Synthetic Genomics (company)

Plant Geneticist and Molecular Biology Expert Eric Mathur Joins ONIT Sciences as Chief Science Officer

Retrieved on: 
Monday, January 16, 2023
Cattle, Synthetic Genomics (company), Dow, Monsanto, Syngenta, SG Biofuels, Molecular biology, Systems ecology, DNA, Verenium Corporation, Health, BASF, Bacteria, Research, Food industry, Agriculture, Cannabis, Coffee, Jatropha

IRVINE Calif., Jan. 16, 2023 /PRNewswire/ -- ONIT Sciences, an agriculture company specializing in organic input technologies, announced today that Eric Mathur, a globally recognized plant geneticist and molecular biologist, has been named the company's Chief Science Officer. Mathur is a subject matter expert in crop improvement and has conducted research worldwide in the industrial plant sciences arena. His skill sets and knowledge traverse genome sciences, molecular biology, plant molecular breeding, environmental microbiology and agricultural biotechnology. His expertise, industry network and insights into plant health make him the perfect professional to lead ONIT's research, development and sales support initiatives.

Key Points: 
  • Mathur is a subject matter expert in crop improvement and has conducted research worldwide in the industrial plant sciences arena.
  • His skill sets and knowledge traverse genome sciences, molecular biology, plant molecular breeding, environmental microbiology and agricultural biotechnology.
  • His expertise, industry network and insights into plant health make him the perfect professional to lead ONIT's research, development and sales support initiatives.
  • Mathur's career spans over 40 years with focus on translational science, making significant advances in plant sciences research.

Sampling Human Appoints Bob Englert as Chief Operating Officer

Retrieved on: 
Monday, January 9, 2023
Health, Biometrics, Health Technology, Other Science, Research, Science, Biotechnology, Synthetic Genomics (company), University, Allen Institute, Liquid biopsy, Abbott Laboratories, Engineering, SGI, Medicine, Sampling, Hematology, Management, Vortex

Sampling Human, Inc., a life science tools company developing single cell technologies, today announced the appointment of Bob Englert as chief operating officer.

Key Points: 
  • Sampling Human, Inc., a life science tools company developing single cell technologies, today announced the appointment of Bob Englert as chief operating officer.
  • “Bob brings decades of extensive business, technology, and operations leadership experience in life science companies and has a special passion for breakthrough products,” said Daniel Georgiev, co-founder and chief executive officer of Sampling Human.
  • “Bob’s expertise in liquid biopsy products and biosensor manufacturing are a highly valuable asset as we build our commercialization pipeline and introduce our game-changing customer experience.”
    Englert joins Sampling Human from Vortex, where he most recently served as the chief executive officer and chief technology officer for over four years.
  • “I am thrilled to be joining the Sampling Human team at this exciting time as we introduce our first products into the market,” Englert said.

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 19, 2022
Merck, Novozymes, RNA, GenScript Biotech, RNA transfection, Synthetic biology, Oligonucleotide, Enzyme, Twist Bioscience, Synthetic Genomics (company), DNA, Agilent Technologies, Vaccine, Investment, Research, Acquisition, Merck Group, Food, Agriculture, Conservation, and Trade Act of 1990, Fine chemical, Agriculture

The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market.

Key Points: 
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market.
  • On the basis of tool, the synthetic biology market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, oligonucleotides & synthetic DNA accounted for the largest share of the synthetic biology market for tools.
  • The medical applications segment accounted for the largest share of the application segment in the synthetic biology market.

Cell-Free Technology Is A Growing Trend In The Synthetic Biology Market

Retrieved on: 
Tuesday, November 1, 2022
Synthetic Genomics (company), Growth, Novozymes, DNA, National Biotechnology Research Park, Precigen, Research, Integrated DNA Technologies, Technology, Risk, Integration, Merck Group, COVID-19, Codexis, Synthetic biology, Government, Workforce, CAGR, NBBI, Escherichia coli, Company, Danaher Corporation, Biotechnology, Gene, Solution, Science, Fine chemical, Pharmaceutical industry, New England Biolabs

LONDON, Nov. 1, 2022 /PRNewswire/ -- Cell-Free Technology is gaining popularity in the synthetic biology market. In this cell-free technology, cell transcription and translation machinery are exploited to express only one or several genes of interest in vitro.  Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame. For instance, in September 2020, OriCiro Genomics, a Japan-based genome technology company offering innovative products and services for synthetic biology, announced the launch of the OriCiro Cell-Free Cloning System, the world's first technology enabling cell-free amplification of large circular DNA, which eliminates the reliance on E. coli cloning.

Key Points: 
  • LONDON, Nov. 1, 2022 /PRNewswire/ --Cell-Free Technology is gaining popularity in the synthetic biology market.
  • Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame.
  • As per the synthetic biology market overview , major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I.
  • North America was the largest region in the synthetic biology market and was worth $4.13 billion in 2021.

Cell-Free Technology Is A Growing Trend In The Synthetic Biology Market

Retrieved on: 
Tuesday, November 1, 2022
Synthetic Genomics (company), Growth, Novozymes, DNA, National Biotechnology Research Park, Precigen, Research, Integrated DNA Technologies, Technology, Risk, Integration, Merck Group, COVID-19, Codexis, Synthetic biology, Government, Workforce, CAGR, NBBI, Escherichia coli, Company, Danaher Corporation, Biotechnology, Gene, Solution, Science, Fine chemical, Pharmaceutical industry, New England Biolabs

LONDON, Nov. 1, 2022 /PRNewswire/ -- Cell-Free Technology is gaining popularity in the synthetic biology market. In this cell-free technology, cell transcription and translation machinery are exploited to express only one or several genes of interest in vitro.  Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame. For instance, in September 2020, OriCiro Genomics, a Japan-based genome technology company offering innovative products and services for synthetic biology, announced the launch of the OriCiro Cell-Free Cloning System, the world's first technology enabling cell-free amplification of large circular DNA, which eliminates the reliance on E. coli cloning.

Key Points: 
  • LONDON, Nov. 1, 2022 /PRNewswire/ --Cell-Free Technology is gaining popularity in the synthetic biology market.
  • Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame.
  • As per the synthetic biology market overview , major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I.
  • North America was the largest region in the synthetic biology market and was worth $4.13 billion in 2021.

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Professional Services, Health, Pharmaceutical, Venture Capital, Oncology, Medical Devices, Research, Genetics, Science, Clinical Trials, Chemistry, Research, Synthetic Genomics (company), R, RNA, Cancer, RNA transfection, GMP, Therapy, Solution, Drug resistance, Method, Patient, Replicate, Technology, Injection, ATP, Novartis, AMRI, Medicine, CMC, Protein, Vaccine

Curias global mRNA development and manufacturing facility is ISO-13485 certified and located near Boston, Massachusetts.

Key Points: 
  • Curias global mRNA development and manufacturing facility is ISO-13485 certified and located near Boston, Massachusetts.
  • Our collaboration with Replicate Bioscience is enabling us to create entirely new methods of manufacturing longer RNAs.
  • We are proud to apply our capabilities and expertise to support the Replicate Bioscience team and its innovative approach.
  • Replicate Bioscience, an ATP company, is designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives.

Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder

Retrieved on: 
Thursday, May 26, 2022
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Diabetes, Adolescence, Cincinnati, Genome, Company, Research, Abdominal pain, Doctor of Philosophy, Patient, Principal investigator, Livestock, Founder CEO, Lactobacillus, Synthetic Genomics (company), FDA, ASD, Maltose, List of life sciences, American Academy of Child and Adolescent Psychiatry, Safety, Limosilactobacillus reuteri, Division, Vomiting, Liberty, Psychiatry, Business, Lists of diseases, Therapy, Autism, Cincinnati Children's Hospital Medical Center, ABT, Autism spectrum, Diarrhea, MD, Kelly, CEO, Pharmaceutical industry, Medical device, Child

This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients, ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).

Key Points: 
  • This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients, ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).
  • The study was conducted at the Cincinnati Childrens Medical Center, with Craig Erickson, MD as the Principal Investigator.
  • Dr. Erickson is Professor of Psychiatry and Director of Research at the Kelly O'Leary Center for Autism Spectrum Disorders and Division of Child and Adolescent Psychiatry at Cincinnati Childrens Hospital Medical Center.
  • Top-line results from the study demonstrated that SB-121 was safe and well tolerated.

Coriell Life Sciences Wins Second MedTech Breakthrough Award For Genomics Innovation

Retrieved on: 
Thursday, May 5, 2022
CLS, Population, Patient, Organization, DNA, Retirement, Precision medicine, Health, Medtech, Synthetic Genomics (company), Genomics, CEO, Pharmaceutical industry, Health insurance

PHILADELPHIA, May 5, 2022 /PRNewswire/ -- As Coriell Life Sciences (CLS) leads the way in unlocking the power of pharmacogenomics (PGx) to improve lives and eliminate healthcare waste, the organization's Corigen® Medication Safety Program has been named "Best Overall Genomics Solution" in the 2022 MedTech Breakthrough Awards. This year's program attracted more than 3,900 nominations from over 15 different countries.

Key Points: 
  • PHILADELPHIA, May 5, 2022 /PRNewswire/ -- As Coriell Life Sciences (CLS) leads the way in unlocking the power of pharmacogenomics (PGx) to improve lives and eliminate healthcare waste, the organization's Corigen Medication Safety Program has been named"Best Overall Genomics Solution" in the 2022 MedTech Breakthrough Awards.
  • CLS' Corigen program drives real clinical and economic benefits for sponsoring organizations and their populations.
  • "On the heels of being named the'Best Overall Genomics Company' by MedTech Breakthrough in 2021, it's a great honor to be recognized again for our groundbreaking Corigen program," said Scott Megill, President & CEO of Coriell Life Sciences.
  • Coriell Life Sciences (CLS) uses innovation in precision medicine to reduce healthcare costs and empower a healthier world.

Viridos Awarded California Competes Grant, Bringing Investment of Nearly $75MM to Imperial Valley

Retrieved on: 
Thursday, April 28, 2022
Research, Alternative Energy, Energy, Environment, Trucking, Science, Engineering, Biotechnology, Transport, Manufacturing, Other Science, Health, Hydrogen, Solution, Economic development, Fairmount Heavy Transport, Aviation, Biotechnology, Photosynthesis, Growth, Unemployment, Goal, Multimedia, Business, Carbon, Industry, Ampaire Electric EEL, Imperial, Synthetic Genomics (company), Climate change, Poverty, Renewable energy

In total, the grant will allow Viridos to create more than 70 high-paying professional jobs and will bring nearly $75 million in investment to the Imperial Valley.

Key Points: 
  • In total, the grant will allow Viridos to create more than 70 high-paying professional jobs and will bring nearly $75 million in investment to the Imperial Valley.
  • Viridos is committed to keeping California as the hub of its strategy by bringing low-carbon and algae-based sustainable heavy transportation fuels to the commercial marketplace.
  • The California Competes Grant Program aims to incentivize businesses to choose California for investment and to stimulate the creation of quality, full-time jobs in the state.
  • Viridos expanded project will bring the investment of high-quality jobs including scientists, engineers, and technicians to Californias Imperial Valley.

Pharmaceutical investments lead 2021 life sciences growth in Indiana

Retrieved on: 
Wednesday, February 2, 2022
Paragon, Curium, Growth, CGMP, Synthetic Genomics (company), RNA transfection, Biotechnology, Unified Diagnostic Services, 3D, Research, Indiana Biosciences Research Institute, Merck Group, Workforce, Printing, Cancer, Radiopharmaceutical, Company, Tech, KOSDAQ, Science, Education, Acquisition, Industry, Stevanato Group, NYSE, Indiana Economic Development Corporation, Multimedia, Solution, Renewable energy, Pharmaceutical industry, Medical imaging, Pfizer

Indiana was the recipient of inbound investment from eight life sciences companies headquartered in six countries: Australia, Brazil, France, Germany, Italy, and South Korea.

Key Points: 
  • Indiana was the recipient of inbound investment from eight life sciences companies headquartered in six countries: Australia, Brazil, France, Germany, Italy, and South Korea.
  • "Indiana's life sciences sector continues to experience significant growth," said Brian Stemme, senior vice president of engagement at BioCrossroads.
  • Major announcements in 2021 included:
    Stevanato Group [NYSE:STVN], an Italian life sciences company, is planning to establish its new U.S. hub in central Indiana.
  • BioCrossroadsinvests capitalandprovidessupport to life sciences businesses, launches new life sciences enterprises ( Indiana Biosciences Research Institute , 16 Tech , Indiana Health Information Exchange ,and OrthoWorx ), expands collaboration and partnerships among Indiana's life science institutions, promotes science education and markets Indiana's life sciences industry.